Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210001/S015

VENTANA anti-MSH6 (SP93) Antibody

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Jan 6, 2026

FDA DECISIONP210001/S015

What did the FDA decide?

FDA records P210001/S015 as a supplement to PMA P210001, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 6, 2026.

FDA approval order statement

approval of manufacturing process changes
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Jan 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P210001/S015
Regulatory pathway
PMA supplement
Product code
QNH
Decision code
OK30
Decision date
Jan 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.

Product code
QNH
FDA device class
3

For the original device and its historical approval scope, see PMA P210001. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210001 · Original PMA

    VENTANA MMR RxDx Panel

  2. P210001/S015 received

    Application receipt date recorded by FDA.

  3. P210001/S015 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P210001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210001

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA approvalAug 17, 2021FDA
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA supplementOct 8, 2026FDA

Explore the linked device profile

Other records with product code QNH

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical SystemsPMA supplementOct 8, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Ventana Medical SystemsPMA supplementJan 6, 2026FDA
Agilent Technologies, Inc.PMA approvalAug 15, 2025FDA
Ventana Medical SystemsPMA approvalApr 22, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records
P210001/S015: VENTANA anti-MSH6 (SP93) Antibody | MedtechLedger